Bicara Therapeutics Inc.
BCAXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for BCAX. That does not mean none is planned.
Get an email about BCAX's next catalysts
Track Bicara Therapeutics (BCAX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
2 upcoming events in our data (earnings, trial start).See the timeline
2 upcoming, 0 past
BCAX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.84 | FQ end Sep/2026 | Call: bmo
Trial Start
Bicara Therapeutics plans to initiate a Q3 alternative dosing study with approximately 150-200 patients, targeting a mid-2027 interim analysis.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ficerafusp alfa | Phase 3 | Metastatic Head and Neck Squamous Cell Carcinoma | - | - |
Frequently asked questions
What is in Bicara Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Bicara Therapeutics Inc.'s (BCAX) pipeline across Phase 3. Its lead program is Ficerafusp alfa (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bicara Therapeutics Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Bicara Therapeutics Inc. (BCAX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BCAX biotech catalysts?→
Add BCAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bicara Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.